FindMyKOL

Luis Marsano, MD

Basic profile

University of Louisville

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionLouisville, KY · SoutheastSpecialtyGastroenterologyFocusGastroenterology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding1999–2002Why? →

Luis Marsano is a Gastroenterology physician affiliated with University of Louisville. OpenAlex indexes 83 publications with 4,131 citations (h-index 28).

Overview

Scholarship

indexed output and impact (OpenAlex)
83publications

Publications indexed by OpenAlex. Counts exclude supporting files.

4,131citations

Citations across these publications.

28h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
10companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 1999–2002

Federally funded research awards.

View funding ↓

Industry payments

10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Salix Pharmaceuticals, a division of Bausch Health US, LLC
    Program year20253 payments
    $138
  • Mallinckrodt Hospital Products Inc.
    Program year20251 payment
    $126
  • Madrigal Pharmaceuticals
    Program year20251 payment
    $125
All 16 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    42.5%
    Proton pump inhibitor10.2%
    Pantoprazole Sodium59%Omeprazole34%Nexium6%
    Part D<11 patients
    Rifamycin Antibacterial9.5%
    Xifaxan100%
    Part D≥28 patients

    + 10 more classes in this area

  • Cardiovascular

    39.7%
    Beta blocker16.8%
    Carvedilol91%Nadolol9%
    Part D<11 patients
    Statin6.5%
    Simvastatin61%Atorvastatin Calcium39%
    Part D≥17 patients

    + 5 more classes in this area

  • Cancer & immunology

    11.1%
    Calcineurin inhibitor6.2%
    Tacrolimus76%Envarsus Xr24%
    Part D<11 patients
    Purine Antimetabolite4.2%
    Azathioprine100%
    Part D≥16 patients

    + 1 more class in this area

Where care is delivered (Part B)69.1% facility · 30.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 1999–2002 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”